Expert forum maps impediments to GM crops
25 July, 2005 by Helen SchullerOver 100 representatives from industry, researchers, farmers' organisations and government took part in the 'Meeting of the Minds' agbiotech forum in Canberra last week to accurately map out differences in positions relating to the introduction of new genetically modified (GM) crops.
US preclinical trials for Mesoblast's stem cells
22 July, 2005 by Ruth BeranMelbourne-based stem cell specialist Mesoblast (ASX:MSB) has entered into agreements with Colorado State University to perform preclinical dose-escalation trials of its universal donor adult stem cell technology for the treatment of long bone fractures, and a new indication, intervertebral spinal fusion.
Stem cells could help treat uterine prolapse
21 July, 2005 by Graeme O'NeillResearchers at Melbourne's Monash Medical Research Institute (MMRI) have identified a readily accessible source of adult mesenchymal stem cells in the lining of the uterus that could help repair uterine prolapse.
It's time for scientists to stand up on cloning
18 July, 2005 by Senator Ron BoswellScientists need to stand up and be counted in the review of cloning legislation to be undertaken by the Lockhart Committee, writes the leader of the National Party in the Senate, Senator Ron Boswell.
LabTech set to commercialise microbial streaking technology
15 July, 2005 by Helen SchullerSouth Australian technology company LabTech Systems (NSX: LTS) is poised to undertake commercialisation of its newly invented brush applicator for the automation of routine microbiology testing in pathology and science laboratories.
Drought tolerance gene identified in wheat
15 July, 2005 by Graeme O'NeillIn the nick of time, climatically speaking, an Australian National University research team has cloned a plant gene that could markedly increase water-use efficiency in major food crops, including cereals.
Stem Cell Sciences raises £6 million on AIM
14 July, 2005 by Ruth BeranDespite terrorist attacks in London last week, BioTech Capital (ASX:BTC) investee company Stem Cell Sciences has raised £6 million (approximately AUD$14 million) as part of its initial public offering and listing on London's Alternative Investment Market (AIM).
Parasite network aims to focus research efforts
12 July, 2005 by Helen SchullerA new, federally-funded Research Network for Parasitology met for the first time in Melbourne last week, bringing together more than 200 researchers in a bid to focus research efforts in the area.
AVT Plasma calls in liquidator after China about-face
06 July, 2005 by Ruth BeranAVT Plasma (ASX:AVT) has suspended trading in its shares, following a board decision to wind up the company and appoint a provisional liquidator.
Stem cell review committee meets in Sydney
05 July, 2005 by Graeme O'NeillThe independent committee appointed to review federal laws restricting stem cell research in Australia met for the first time yesterday, in Sydney.
Why biotech is hot in India
01 July, 2005 by Russell McInnesAfter a recent first-hand look, Russell McInnes shares some perspectives on India's burgeoning biotech industry.
AVT Plasma sets its sights on China
30 June, 2005 by Ruth BeranProducing products from human blood plasma is a lucrative business and the Chinese market provides a significant long-term opportunity, AVT Plasma's CEO tells Ruth Beran.
Stem Cell Sciences moves to list on AIM
24 June, 2005 by Ruth BeranBiotech Capital (ASX:BTC) investee company Stem Cell Sciences is looking to raise up to £10 million on London's Alternative Investment Market (AIM).
Researchers make oocytes from embryonic stem cells
23 June, 2005 by Graeme O'NeillMonash University fertility researchers have succeeded in producing oocytes -- eggs -- from mouse embryonic stem (ES) cells, offering hope to couples who are unable to conceive, even by in vitro fertilisation, because the partner lacks viable eggs.
Agenix's Thromboview found safe
20 June, 2005 by Ruth BeranBrisbane Agenix (ASX:AGX, OTC(NASDAQ):AGXLY) has found that its Thromboview blood clot diagnostic is safe and not associated with an immune response, according to results from its Phase Ib deep vein thrombosis (DVT) study.
